PsyMuKB

PPI network (data source: BioGrid)

A gene is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the mean normalized expression(base 2 log of (TPM+1)) +1 in all brain tissue from GTEx v7 or BrainSpan data.

A protein is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the normalized expression (base 10 log of iBAQ intensity) ≥0.5 in at least one brain tissue from ProteomicsDB data. Otherwise, a gene or protein is determined as either with below-cutoff expressions or no available data.

	The queried gene/protein
	The interacting partner is expressed at mRNA-level
	The interacting partner is expressed at protein-level
	The interacting partner is expressed at both mRNA and protein level
	The interacting partner is with either below-cutoff expressions or no expression data at both mRNA and protein level
	The interacting partner is hit by coding DNMs
	Physical interaction between queried gene/protein and its partner
	Physical interaction between two interacting partners

Symbol A	GeneA coding DNM count	Symbol B	GeneB coding DNM count	Interaction detection method	Publication	Evidence
TFAP2B	2	LZTR1	16	two hybrid	Ravasi T (2010)	1
CREBBP	29	CITED2	0	affinity chromatography technology	Bhattacharya S (1999)	1
CITED2	0	TFAP2B	2	pull down	Braganca J (2002)	1
TFAP2B	2	YEATS4	0	two hybrid, affinity chromatography technology, affinity chromatography technology, pull down	Ding X (2006), Ding X (2006), Ding X (2006), Ding X (2006)	4
KCTD1	3	TFAP2B	2	affinity chromatography technology	Ding X (2009)	1
TFAP2A	1	UBE2I	0	two hybrid	Eloranta JJ (2002)	1
UBE2I	0	CREBBP	29	affinity chromatography technology, pull down, enzymatic study, two hybrid	Hsieh YL (2013), Hsieh YL (2013), Hsieh YL (2013), Liu ST (2012)	4
TFAP2B	2	UBE2I	0	two hybrid	Eloranta JJ (2002)	1
TFAP2A	1	KCTD1	3	two hybrid, pull down, affinity chromatography technology, affinity chromatography technology, imaging technique	Ding X (2009), Ding X (2009), Ding X (2009), Ding X (2009), Ding X (2009)	5
TFAP2A	1	AURKA	1	affinity chromatography technology, affinity chromatography technology	Zou L (2011), Zou L (2011)	2
TP53	0	TFAP2B	2	affinity chromatography technology	Zhou J (2010)	1
CREBBP	29	CITED1	0	affinity chromatography technology	Yahata T (2000)	1
AURKA	1	TFAP2B	2	pull down	Kamran M (2017)	1
CITED4	0	TFAP2B	2	pull down	Braganca J (2002)	1
CREBBP	29	TP53	0	enzymatic study, pull down, genetic interference, pull down, enzymatic study, fluorescent resonance energy transfe, enzymatic study, affinity chromatography technology, imaging technique, pull down, pull down, pull down, pull down, pull down, enzymatic study, pull down, affinity chromatography technology, unspecified method, pull down, pull down, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, x-ray crystallography, pull down, affinity chromatography technology, enzymatic study, enzymatic study, pull down, x-ray crystallography, x-ray crystallography, enzymatic study, affinity chromatography technology, affinity chromatography technology, pull down	Ito A (2002), Livengood JA (2002), Livengood JA (2002), Giebler HA (2000), Tang Y (2008), Jenkins LM (2009), Shi D (2009), Zhao Y (2006), Saifudeen Z (2005), Scolnick DM (1997), Scolnick DM (1997), Gu W (1997), Gu W (1997), Matsuda S (2004), Pasqualucci L (2011), Lee SK (1999), Dai C (2011), Lee CW (2010), Ferreon JC (2009), Ruas JL (2010), Ruas JL (2010), Huang WC (2007), Huang WC (2007), Mujtaba S (2004), Mujtaba S (2004), Mujtaba S (2004), Mujtaba S (2004), Col E (2002), Jansma AL (2014), Jansma AL (2014), Krois AS (2016), Hasegawa K (2008), Huang X (2013), Huang X (2013), Piskacek M (2016)	35
CITED1	0	TFAP2B	2	pull down	Braganca J (2002)	1
TFAP2A	1	TP53	0	imaging technique, pull down, two hybrid, affinity chromatography technology, pull down, affinity chromatography technology	McPherson LA (2002), McPherson LA (2002), McPherson LA (2002), McPherson LA (2002), Stabach PR (2006), Stabach PR (2006)	6
UBE2I	0	AURKA	1	enzymatic study	Ban R (2011)	1
CITED2	0	TFAP2A	1	two hybrid, far western blotting, pull down	Braganca J (2003), Braganca J (2003), Braganca J (2002)	3
TP53	0	AURKA	1	two hybrid, affinity chromatography technology, affinity chromatography technology, pull down, genetic interference, pull down, pull down, affinity chromatography technology, affinity chromatography technology, enzymatic study, affinity chromatography technology, affinity chromatography technology	Chen SS (2002), Chen SS (2002), Chen SS (2002), Chen SS (2002), Chen SS (2002), Katayama H (2004), Katayama H (2004), Katayama H (2004), Katayama H (2004), Hsueh KW (2013), Huttlin EL (2015), Huttlin EL (2017)	12
TFAP2B	2	SSBP4	0	two hybrid	Ravasi T (2010)	1
TFAP2B	2	CREBBP	29	affinity chromatography technology	Guo W (2014)	1
TFAP2A	1	TFAP2B	2	affinity chromatography technology	Keyel PA (2008)	1
UBE2I	0	TP53	0	two hybrid, two hybrid, two hybrid, enzymatic study, two hybrid, affinity chromatography technology, enzymatic study, enzymatic study, affinity chromatography technology, affinity chromatography technology, enzymatic study, pull down, enzymatic study, enzymatic study, enzymatic study, enzymatic study, enzymatic study, enzymatic study	Minty A (2000), Gallagher WM (1999), Shen Z (1996), Bernier-Villamor V (2002), Wang J (2008), Spektor TM (2011), Jakobs A (2007), Mohideen F (2009), Lin JY (2004), Bennett RL (2012), Heo KS (2013), Morimoto M (2003), Rodriguez MS (1999), Muller S (2000), Fernandez-Lloris R (2006), Mohan RD (2007), Brandt M (2013), Weger S (2005)	18
CITED4	0	TFAP2A	1	pull down	Braganca J (2002)	1
UBE2I	0	KCTD1	3	two hybrid, two hybrid	Rolland T (2014), Yu H (2011)	2